Thermo Fisher: An Up To 35% Undervalued Healthcare Gem I Like On Weakness

Summary:

  • Thermo Fisher Scientific stands strong in the healthcare sector, prioritizing growth, innovation, and sustainability, justifying its valuation despite recent market challenges.
  • TMO showcases resilience, leveraging long-term healthcare market trends, hinting at consistent annual growth potential despite the current stock price decline.
  • TMO’s strategic strengths, including market localization in China and M&A proficiency, along with favorable valuation projections and a robust balance sheet, set the stage for continued outperformance.

Hand putting coins on stack stair as step growing growth and wooden cube block with word HEALTH. Investment health and insurance fund concept

marchmeena29

Introduction

It’s time to talk about Thermo Fisher Scientific (NYSE:TMO), a stock I haven’t covered since early July. Here’s a part of my takeaway I wrote back then:

TMO’s focus on secular growth factors, high-impact innovation, capital deployment, operational excellence, and ESG


Analyst’s Disclosure: I/we have a beneficial long position in the shares of DHR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Test Drive iREIT© on Alpha For FREE (for 2 Weeks)

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial.

And this offer includes a 2-Week FREE TRIAL plus Brad Thomas’ FREE book.

Leave a Reply

Your email address will not be published. Required fields are marked *